Pfizer's inclacumab fails Phase III study for sickle cell disease, disappointing the community while the company remains ...

This story was originally published by ProPublica, a Pulitzer Prize-winning investigative newsroom. Sign up for The Big Story ...

The Nobel Prize-winning technology underpinning COVID-19 vaccines is also fueling a host of biotechs developing treatments ...

By Padmanabhan Ananthan (Reuters) -In the latest setback for Pfizer's sickle cell anemia treatments, experimental drug ...

‘It’s not illegal to be homeless’: disquiet as Trump crews clear DC encampments AG showdown: DC attorney general rejects US ...

The FDA’s announcement of Papzimeos’ approval contained an unusual quote from newly reinstated CBER director Vinay Prasad. Elsewhere, Eli Lilly and Superluminal Medicines struck a deal.

Pfizer's experimental drug to treat sickle cell anemia failed to meet the main goal in a late stage trial, the drugmaker said ...

Pfizer said on Friday that its experimental sickle cell disease drug failed to meet the main goal in a late stage trial in ...

The combination of Padcev and Keytruda delivered a phase 3 win in muscle-invasive bladder cancer. China did not renew the conditional approval for a controversial Alzheimer's disease drug. | The ...

AbbVie unveiled a $195 million investment to expand active pharmaceutical ingredient manufacturing in the U.S. Bloomberg reported that BlinkRx, a company that has Donald Trump Jr. on its board, just ...

Pfizer ( PFE -0.18%) was a hot stock during the pandemic, but it has been crashing in recent years. The company's COVID ...

They’re turning their backs on a technology thought to have saved millions of lives—with the potential to save many more.